Kornimate/medical-research-clean huggingface dataset:
precision care for major depressive disorder

Conditions: Major Depressive Disorder; Depression; Depressive Disorder, Major

Summary: this study aims to assess whether phenotyping-guided intervention selection is superior to intervention selection without phenotyping guidance (i.e., routine clinician and patient judgment regarding treatment selection) for depression.

this study will classify patients seen in the depression clinic of the ucsf department of psychiatry and behavioral sciences into one of five phenotypes (subtypes), including: 1) anhedonia, 2) cognitive deficits, 3) stress sensitivity, 4) anxious distress, and 5) grief. after phenotyping, participants will be randomized to receive phenotype-specific intervention (psi) or care as usual (cau).

Eligibility criteria:
inclusion criteria: * participant is able to provide informed consent * english speaker * 18 years of age or older at time of consent * meets dsm-5 criteria for major depressive disorder * the subject meets eligibility criteria for at least one study phenotype as determined by assessments, imaging and/or clinical judgment. * phq-8 score at baseline of \>= 10 * scheduled for or completed intake in ucsf outpatient psychiatry exclusion criteria: * unstable or untreated medical or psychiatric condition based on clinical assessment by investigator(s) * significant risk of suicidal or violent behavior as determined by clinical judgement * in the investigators' opinion, the subject is not capable of adhering to the protocol requirements, or the subject has a history of poor or suspected poor compliance in clinical research studies, or the subject has a history of poor or suspected poor compliance to antidepressant medication or that study participation is not in their best interest (e.g., different treatment is indicated given their clinical presentation) * pregnant or breastfeeding or planning to become pregnant during the study
effect of fecal microbiota transfer on progression of parkinson disease

Conditions: Parkinson Disease

Summary: the aim of the study is to assess impact of fecal microbiota transfer (fmt) on clinical symptoms of parkinson's disease. assesment of tremor, slowness of movements and balance problems before and after fmt will be performed. the effect of fmt on frequency of constipations, which are common among parkinson disease patients and have negative impact on quality of life and drug absorption will also be assessed. detailed assessment of absorption of levodopa, which is the golden standard of treatment of parkinson disease, is planned. it is planned to recruit 40 patients with diagnosis of parkinson disease and indications for colonoscopy (constipations, age \>50 years). patients will be randomly assigned to the group receiving treatment with fmt or identically looking placebo. it will be administered to intestine during colonoscopy. patients will be assessed by neurologist few times after the procedure. psychological assessment and examination of gait and balance by physiotherapist is also planned. the last assessment will be performed after 12 months to see if the clinical effect can be observed for such a long time. the composition of the intestinal microbiota will be carefully assessed before and after the procedure in order to identify pathogens that may affect the course of the disease.


Eligibility criteria:
inclusion criteria: * idiopathic pd * consent to undergo colonoscopy exclusion criteria: * perforation or obstruction of gastroenteric tract, * radiotherapy of abdomen or pelvis region * severe heart, liver or kidney failure * coagulation disorders * immunity disorders * current viral, bacterial or fungal infection * abdominal aortic aneurysm qualifying for surgery, pregnancy and lactation treatment with duodopa, deep brain stimulation or apomorphine * colonoscopy confirmed colon polyps, except for lesions \<5 mm qualified for the nbi international colorectal endoscopic i group or other potentially neoplastic lesions after evaluation in white light and narrow beam imaging (nbi) * severe food allergy with a history of anaphylaxis after consumption of the product. * microbiological stool evaluation with detection of: methicillin-resistant staphylococcus aureus (mrsa), klebsiella pneumoniae carbapenemase (kpc), metallo-β-lactamase (mbl), extended-spectrum beta-lactamase (esbl), vancomycin-resistant enterococci (vre), salmonella, shigella, yersinia. if any other atypical pathogen are to be detected in general stool culture, it will be assessed on an individual basis.

Keywords: fecal microbiota transplant
effects of glutathione on immunity in individuals training for a marathon

Conditions: Healthy

Summary: the aim of this study is to determine the effects of glutathione supplement on the immune cell response and symptomatology of upper respiratory health, and antioxidant capacity in healthy people in exercise-induced model.

a minimum of 60 individuals will be recruited and enrolled to complete the entire protocol in a randomized, double-blinded, 18 week placebo-controlled trial. subjects will receive either a placebo or glutathione while participating in a stepwise exercise approach that mixes periods of high and low training volume to train subjects and improve running efficiency. upper respiratory tract infection-related health conditions will be monitored and assessed throughout the study period. blood and saliva samples will be collected at baseline, and before and after timed 15k and half marathon runs at 12 and 16 weeks respectively.

Eligibility criteria:
inclusion criteria: * generally healthy, male or female. * between the ages of 19-45 years. * have no medical restrictions and no health conditions that would inhibit participant from marathon run. * be willing and able to comfortably abstain from any food supplements. * not participating as a subject in another study. exclusion criteria: * bmi \ 28.5. * current or prior use of tobacco products or other inhaled substance. * more than a moderate intake of alcohol (\>1 drink per day in women; \>2 drinks per day in men). * metabolic or inflammatory disease. * excellent fitness based on the american college of sports medicine criteria for vo2max based on age and gender. * recent weight loss of \>10 pounds in the last 3-months. * daily intake of ibuprofen, acetaminophen, aspirin, polyphenol supplements, multivitamins, and/or antioxidant supplements. * actively attempting (or planning) to lose or gain weight and/or alter body composition. * currently taking cholesterol-lowering medications. * currently taking prescription anti-inflammatory medications. * currently using mouthwash on a regular basis (\>4 times per week). * orthopedic problems that would limit running capacity. * currently in very poor or poor fitness. * highly aerobic exercise trained. * pregnant or planning to become pregnant during the study period. * breast feeding * currently taking blood pressure medications. * contraindications to strenuous exercise. * anemic (blood hemoglobin \<10 g/dl and/or hematocrit \<35%). * diagnosed with asthma or other lung disease.
safety and efficacy of celecoxib versus diclofenac in the treatment of ankylosing spondylitis

Conditions: Spondylitis, Ankylosing

Summary: to compare the safety and efficacy of once-daily and twice-daily celecoxib versus diclofenac for the treatment of ankylosing spondylitis


Eligibility criteria:
inclusion criteria: * diagnosis of ankylosing spondylitis defined according to modified new york criteria, and with axial involvement * requiring daily treatment with nonsteroidal anti-inflammatory drugs during the previous 30 days exclusion criteria: * patients with inflammatory enterophathy, and with extra-articular manifestations * patients with known vertebral compression * received corticosteroids 6 weeks prior to the baseline visit; patients on stable dose of prednisolone equivalents ≤ 10 mg/ day for at least 14 days before randomization were permitted
seroquel in bipolar depression versus lithium

Conditions: Bipolar Disorder; Bipolar Depression; Depression

Summary: this study is being carried out to see if quetiapine fumarate (seroquel) is effective in treating bipolar depression during an 8-week acute phase compared with placebo and lithium, followed by continuation treatment for 26 up to 52 with quetiapine fumarate (seroquel) compared to placebo.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of bipolar i disorder or bipolar ii disorder, currently depressed, aged 18 to 65 years old and outpatient status at enrolment and randomization. exclusion criteria: * patients with a current dsm-iv axis i disorder other than bipolar disorder that is symptomatic or requiring treatment within 6 months of enrolment, * history of non-response to an adequate treatment * patients who, in the investigator's judgment pose a current serious suicidal or homicidal risk * pregnancy or lactation * clinically relevant disease or clinical finding

Keywords: bipolar disorder bipolar depression depression
efficacy of vitamin d3 for the treatment of psoriatic patients with vitamin d deficiency and insufficiency

Conditions: Psoriasis Vulgaris; Vitamin D Deficiency

Summary: the purpose of this research is to study whether vitamin d supplement can improve clinical outcome (pasi score) in psoriasis vulgaris with vitamin d insufficiency and deficiency.

while psoriasis is not a lethal disease, the disease itself can impact patients' quality of life. nowadays there are several researches on vitamin d functions. recently review article of vitamin d deficiency by holick mf., stated that vitamin d can play a role in decreasing the risk of osteoporosis and other chronic diseases such as malignancy, autoimmune disease, infectious disease, cardiovascular disease, and psoriasis. moreover, vitamin d effects on keratinocyte by decreasing abnormal cell proliferation, differentiation, apoptosis and controlling immunological process via the suppression of t-cell activation, regulation of cytokine secretion patterns, induction of regulatory t-cell, modulation of t-cell proliferation and interference with t-cell apoptosis. thus, our objective is to look for other alternative treatment, which may have less side effects and acceptable clinical outcomes.

Eligibility criteria:
inclusion criteria: * mild to moderately severe (pasi ≤ 10), chronic plaque type psoriasis vulgaris patient, who is a new case or has at least treatment-free period as following: 4 weeks for topical calcipotriol, topical corticosteroid or 8 weeks for systemic therapy (i.e. cyclosporine, acitretin, methotrexate) or 12 weeks for psoralen ultraviolet a (puva), phototherapy or biological treatment. * age 18-year-old to 70-year-old. * psoriasis vulgaris patient with vitamin d insufficiency or deficiency. exclusion criteria: * pregnancy or lactating mother. * subject with history of major gastrointestinal surgery or gastric bypass surgery. * subject with history of pustular psoriasis. * subject with active psoriatic arthritis. * subject with prior phototherapy within the past 3 months. * subject with history of hypocholesterolemia (serum cholesterol \< 120 mg/dl) or primary hyperparathyroidism. * subject who regularly takes vitamin d supplement exceed 3,000 iu/day and high vitamin d diet, for example cod liver oil. * subject with liver disease, cystic fibrosis, crohn's disease, celiac sprue, renal disease, pancreatic disease, and inflammatory bowel disease. * subject taking following medication: corticosteroid, orlistat, rifampicin, isoniazid, ketoconazole, statin, and cholestyramine.

Keywords: psoriasis vulgaris vitamin d deficiency vitamin d insufficiency vitamin d supplement psoriasis area and severity index (pasi score) dermatologic life qualify index (dlqi)
outcomes and data collection for fecal microbiota transplantation for the treatment of recurrent clostridium difficile

Conditions: Clostridium Difficile Infection Recurrence; Clostridium Difficile Infection

Summary: the purpose of this study is to see if stool transplant performed by colonoscopy is effective at treating recurrent clostridium difficile (c. diff) infection of the colon. during the procedure a stool sample is taken from a healthy donor (usually family member or close friend) and transplanted directly into the colon of the patient with c. diff infection. the goal of this experimental procedure (called fecal microbiota transplantation) is to replenish the good bacteria in the colon that can help prevent c. diff infection from coming back after treatment.

fecal microbiota transplantation (fmt) involves administering fecal material from a healthy individual into the gastrointestinal tract of the patient. this has been done in the past for recurrent colitis secondary to clostridium difficile infection (cdi) using different methods such as through nasogastric tube, fecal retention enemas, and by colonoscopy. this method of treatment was introduced over 50 years ago with high success rates, although it has not been until recent that more case studies have been performed, with continued success rates of approximately 90%. studies have found this therapy to be effective with resolution of symptoms in most patients, and have found it to be both cost effective and safe. the purpose of this study is to use a standardized published protocol for fecal microbiota transplantation performed by colonoscopy and record the success rate and outcomes of fmt therapy for patients with recurrent cdi at the umassmemorial medical center. in addition, the cost of this therapy will be compared to conventional antibiotic treatment. the reduction in hospitalizations will also be monitored compared with historical controls. the hypothesis of this study is that fmt therapy will show resolution of infection in most patients with recurrent cdi, with an overall reduction in cost to the hospital for recurrent admissions for clostridium difficile colitis as compared to historical controls. historical controls will be defined as patients with recurrent positive clostridium difficile stool samples treated in the traditional fashion with antibiotics.

Eligibility criteria:
inclusion criteria: * two or more recurrences of c. difficile infection (cdi) with recurrence defined as a positive test result, e.g. polymerase chain reaction (pcr) test and with appropriate symptoms within 2-8 weeks of last positive result, provided that symptoms from earlier episode resolved with or without therapy. * failed standard therapy with oral metronidazole and/or oral vancomycin * one or more episodes of severe cdi resulting in hospitalization and not responding to standard antibiotic therapy. hospitalization for cdi occurs in the setting of severe diarrhea, abdominal pain and signs of systemic toxicity exclusion criteria: * age \<16 years old * patients with acute severe colonic dilation at risk for colonic perforation
a study evaluating the safety and efficacy of rdx013 for the treatment of hyperkalemia

Conditions: Hyperkalemia

Summary: the purpose of this study is to evaluate the ability of rdx013 to lower serum potassium in patients with chronic kidney disease with elevated serum potassium levels


Eligibility criteria:
inclusion criteria: 1. males or females aged 18 to 85 years, inclusive 2. serum potassium value 5.1 to \<6.5 mmol/l 3. chronic kidney disease with egfr ≥20 to \<60 ml/min/1.73m2 4. able to understand and comply with the protocol 5. willing and able to sign informed consent exclusion criteria: 1. pseudo-hyperkalemia signs and symptoms 2. treatment with potassium-lowering drugs within 7 days prior to enrollment/randomization 3. treatment with glucocorticoids 4. uncontrolled type 2 diabetes, defined as most recent historical hba1c \> 10%, or hospitalization to treat hyper- or hypo-glycemia in the past 3 months 5. diabetic ketoacidosis 6. severe heart failure, defined as nyha (new york heart association) class iv or hospitalization to treat heart failure in previous 3 months 7. history of bowel obstruction, severe gastrointestinal disorders, or major gastrointestinal surgery (e.g., large bowel resection) 8. females who are pregnant, lactating, or not willing to use appropriate contraception
physical activity, insulin resistance and function of fat tissue in the offspring of patients with type 2 diabetes

Conditions: Type 2 Diabetes Mellitus; Cardiovascular Diseases

Summary: offspring of patients with type 2 diabetes have increased risk of developing diabetes and are typically more insulin resistant than their peers with no diabetes family history. we have recently demonstrated that, in contrast to their sedentary counterparts, physically active offspring are not insulin resistant. in the proposed controlled clinical study, we will examine the effects of a moderate exercise programme on insulin resistance, and other metabolic risk factors, in sedentary offspring and matched control subjects. we hypothesise that offspring will exhibit an augmented response to exercise, thereby normalising their predisposition to an adverse metabolic profile. we will also investigate expression of adipokines and other genes in adipose tissue to determine whether these contribute to the increased insulin resistance observed in offspring and whether they are influenced by exercise. the results will help to determine the efficacy of exercise in normalising metabolism in offspring and will help elucidate the mechanisms involved.


Eligibility criteria:
inclusion criteria: * 2 subject groups - 'control' and 'offspring' * offspring - at least 1 parent diagnosed with type 2 diabetes before age 65 * controls - no history of type 2 diabetes in 1st or 2nd degree relatives * in generally good health * non-smoker * fasting glucose \< 7 mmol/l * blood pressure \<160/90 mm hg * no established chd (e.g. mi, stroke, cabg, pcta) exclusion criteria: * established chd (e.g. mi, stroke, cabg, pcta) * diabetes * smoking * hypertension (bp \> 160/90 mmhg) * pregnancy

Keywords: exercise physical activity insulin resistance adipose tissue gene expression
assessment of complete response mri criterion after neoadjuvant therapy in locally advanced rectal cancer

Conditions: Rectal Neoplasms

Summary: standard care for locally advanced rectal cancer consists in a neoadjuvant therapy followed by surgery. morbidity and mortality remain high after rectal surgery, and often linked with quality of life impairment. 10 to 30% present a pathological complete response after neoadjuvant therapy. some surgical teams propose "watch and wait" approach for patients selected with clinical complete responses criterion. the problem is to be sur the response is complete. mri seems to be accurate to select complete responders. we will try to find mri criterion of complete responses.


Eligibility criteria:
inclusion criteria: * rectal adenocarcinoma * locally advanced * neoadjuvant therapy * mri restaging * rectal surgery * definitive anatomopathology study

Keywords: mri complete response
laparoscopic versus open liver resection in the treatment of hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this study is to investigate the clinical value of laparoscopic liver resection in the treatment of hepatocellular carcinoma by assessing its surgical and oncologic outcomes comparing with open liver resection.


Eligibility criteria:
inclusion criteria: * liver solid tumor, with clinical diagnosis of hepatocellular carcinoma * located at segment ⅱ、ⅲ、ⅳb、ⅴ or ⅵ * the tumor location and size do not affect the dissection of hepatic hilar region * tumor size less than 10cm * without portal vein tumor thrombus * without intrahepatic or distant metastasis * willingness to participate in the study * able to understand the nature of the study and what will be required of them * body mass index of between 18 and 35 * child-pugh classification of a to b * american society of anesthesiologists (asa) grading of i to iii exclusion criteria: * pregnant or lactating women * unwillingness to participate * inability to give written informed consent * child-pugh classification of c * asa grading of iv to v * tumor invasion of the inferior vena cava or confluence part of hepatic vein * decompensated liver cirrhosis

Keywords: hepatocellular carcinoma
long-term safety of febuxostat in subjects with gout.

Conditions: Gout

Summary: the purpose of this study is to evaluate the long-term safety of febuxostat, once daily (qd), in maintaining serum urate levels within clinically acceptable levels in subjects with gout.

uric acid is the end product of purine degradation in humans. hyperuricemia, a urate concentration in serum exceeding the limit of urate solubility (approximately 7.0 milligrams per deciliter \[mg/dl\]), is a common biochemical abnormality. aberrations in any of the multiple mechanisms involved in the production and/or excretion of uric acid may increase serum urate concentrations, with persistent hyperuricemia as a marker for extracellular fluid monosodium urate supersaturation. as such, hyperuricemia is a necessary (but often not sufficient) risk factor for monosodium urate crystal deposition in tissues and is the fundamental pathophysiological process underlying the clinical manifestations of gout, which is a chronic disease characterized by urate crystal formation and deposition in joints and bones. gout may progress from episodic attacks of acute inflammatory arthritis to a disabling chronic disorder characterized by deforming arthropathy; destructive deposits of urate crystals (tophi) in bones, joints, and other organs; structural and functional renal impairment due to interstitial urate crystal deposition; and urinary tract stones composed entirely or in part of uric acid crystals. management of gout requires chronic treatment aimed at lowering serum urate into a subsaturating range (usually \<6.0 mg/dl) in which crystal formation and deposition are prevented or reversed. febuxostat (tmx-67) is a non-purine selective xanthine oxidase inhibitor being developed as an orally administered agent for management of hyperuricemia in patients with gout. subjects who want to participate in this study will have successfully completed study tmx-00-004 (nct00174967). all participants will initially receive an 80 mg dose. dose titrations will occur in order to obtain and maintain clinically acceptable serum urate levels.

Eligibility criteria:
inclusion criteria: * hyperuricemia (serum uric acid ≥8.0 mg/dl upon entering parent study tmx-00-004). * must meet american college of rheumatology criteria for gout. * must have adequate renal function (serum creatinine \<1.5 mg/dl). * must have completed four weeks of double-blind dosing in study tmx-00-004. * must not have experienced any serious study drug-related adverse events in study tmx 00-004. * females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from screening throughout the duration of the study. exclusion criteria: * history of xanthinuria * alcohol consumption \>14/week * has a history of significant concomitant illness * has active liver disease. * has a body mass index greater than 50 kg/m2 * any other significant medical condition that would interfere with the treatment, safety or compliance with the protocol, as defined by the investigator.

Keywords: uric acid xanthine oxidase tophi drug therapy